Distributorship, sales and services agreement extends for another 10 years
Sysmex Corporation (HQ: Kobe, Japan; President and CEO: Hisashi Ietsugu) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the signing of a restated 10 years distribution, sales and services agreement (â€śDSS Agreementâ€ť). Under the agreement, Roche will continue to distribute the Sysmex hematology products, including instruments, reagents and data management solutions in selected countries and regions1.
Since entering into the DSS Agreement in 1999, Sysmex and Roche have applied their mutual strengths to expand market share while building a favorable relationship.
â€śBased on Sysmexâ€™ industry leadership allied with Rocheâ€™s unique position as the global market leader in in vitro diagnostics, the collaboration underlines our objective of bringing a maximum of industry expertise in hematology to health professionals. This unique synergy supports both companiesâ€™ objectives to continue to grow above marketâ€ť, comments Hisashi Ietsugu, President and CEO of Sysmex Corporation.
The recently released new XN series from Sysmex with its modular and scalable system design addresses customer needs for access to a full menu across customer segments from small to large workloads. Concurrent with Rocheâ€™s future platform strategy, the new Sysmex XN series contributes to Rocheâ€™s concept of addressing the various needs of todayâ€™s laboratories with customized modular solutions. The renewed agreement allows both companies to apply their strengths more effectively.
â€śThe breadth of the Sysmex portfolio combined with Rocheâ€™s cobas analyzer platforms allows customers to choose from the broadest set of instruments available for each laboratory setting. This embraces our goal to strengthen and to expand Rocheâ€™s offering in central laboratories in hospitals and commercial laboratoriesâ€ť, states Colin Brown, Head of Roche Professional Diagnostics, Rocheâ€™s market-leading business area of integrated, modular and highly-efficient testing solutions for clinical and immuno in-vitro diagnostics for centralised and decentralised settings.
(1) Territories include Spain, Turkey, Greece, South Africa, Russia, Finland, Baltic Territory, Brazil, Mexico, Chile, Argentina, Uruguay, Colombia, Peru, Ecuador, Venezuela, Central America, Australia and New Zealand.
For more information:
Last updated on: 13/04/2012